contact us

Advance new therapies
Stay human

BiomimX unlocks in vitro models reflecting
human complexity, towards the design
of effective treatments tailored for patients.

Beating Organs-on-Chip are the next generation
of pre-clinical models: human,dynamic,3D.

Discover the therapies of tomorrow
by catching human data today

Every tissue in the body is subjected to motion. Our Beating Organs-on-Chip finally bring this motion into the 3D native microenvironment offering clinically relevant human in vitro setups.

Every tissue in the body is subjected to motion. Our Beating Organs-on-Chip finally bring this motion into the 3D native microenvironment offering clinically relevant human in vitro setups.

Our Services

biologist

Get human relevant data from our  uBeat® models. BiomimX® is the ideal partner to boost your drug discovery & development.

Explore

Our Technology

uBeat® ground-breaking technology brings into microscaled setups a unique combination of mechanical stimulation and 3D architecture.

Explore

Our Products

BiomimX uBeat platform

uBeat® innovative cell culture setups create the path to develop the next generation of advanced 3D dynamic models.

Explore

Meet us

November 11 2024

Join our co-founders, CEO Paola Occhetta and CTO Marco Rasponi for the grand presentation at The Europas Awards on the afternoon of November 11th at La Distillerie in Lisbon! 🏆

stay tuned BiomimX

Latest News

Innovation Radar Prize 2024
🎉 Exciting News: BiomimX is a Finalist for the Innovation Radar Prize 2024! 🎉

Join us for the grand presentation at The Europas Awards on the afternoon of November 11th at La Distillerie in Lisbon! 🏆 Every finalist will deliver a 3-minute pitch, and we are proud to be represented by our co-founders, CEO Paola Occhetta and CTO Marco Rasponi. Our CEO will take the stage to deliver BiomimX’s 3-minute pitch!

Register for the Awards Presentation
BiomimX & Synartro
New Publication
📢 Publication Alert!!

BiomimX is excited to announce that the results of our collaboration with Synartro have just been published on Advanced Healthcare Materials.
The collaboration was born from the need to test the efficacy of SYN321, a pioneering Intra-Articular (IA) drug candidate for Osteoarthritis (OA) therapy, on an in vitro model able to recapitulate the key pathological features of OA. We brought our technological and biological expertise into this collaboration by testing the effect of SYN321 on our model of OA, developed in a novel platform, the uBeat® MultiCompress, tailored for the injection of viscous therapeutics.
The findings of this research, have also been accepted by Swedish regulatory authorities as part of an Investigational New Drug (IND) application, clearing the way for phases 1 and 2a of clinical trials.

Publication
Previous slide
Next slide